UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

The New England journal of medicine, 2014-07, Vol.371 (3), p.224-233

2014

Volltextzugriff (PDF)

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

BMC cancer, 2019-01, Vol.19 (1), p.66-66, Article 66

2019

Volltextzugriff (PDF)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Endocrine-related cancer, 2016-03, Vol.23 (3), p.191-199

2016

Volltextzugriff (PDF)

Nausea and Vomiting of Pregnancy: Endocrine Basis and Contribution to Pregnancy Outcome

Obstetrical & gynecological survey, 2001-12, Vol.56 (12), p.775-782

2001

Volltextzugriff (PDF)

Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15180-e15180

2015

Volltextzugriff (PDF)

Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15181-e15181

2015

Volltextzugriff (PDF)

Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15177-e15177

2015

Volltextzugriff (PDF)

Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4104-4104

2015

Volltextzugriff (PDF)

Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15182-e15182

2015

Volltextzugriff (PDF)

Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15178-e15178

2015

Volltextzugriff (PDF)

Light-hearted death talk in a palliative day care context

Journal of advanced nursing, 1997-12, Vol.26 (6), p.1091-1097

1997

Volltextzugriff (PDF)

Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.233-233

2015

Volltextzugriff (PDF)

Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.367-367

2015

Volltextzugriff (PDF)

Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4107-4107

2014

Volltextzugriff (PDF)

The mortality of mental illness in older age

Reviews in clinical gerontology, 1995-02, Vol.5 (1), p.103-112

Langley, A M

1995

Volltextzugriff (PDF)

Light-hearted death talk in a palliative day care context

Journal of advanced nursing, 1997-12, Vol.26 (6), p.1091-1097

1997

Volltextzugriff (PDF)

'Suicide tourists' go to the Swiss for help in dying

The New York times, 2003-02, p.A3-A3

Langley, Alison

2003

Volltextzugriff (PDF)

Back to the Borse

Institutional Investor, 2005-11, p.1

Langley, Alison

2005

Volltextzugriff (PDF)

Going local: 1

Institutional Investor, 2005-02, p.1

Langley, Alison

2005

Volltextzugriff (PDF)

Reviving Swiss Life: 1

Institutional Investor, 2004-07, p.1

Langley, Alison

2004

Volltextzugriff (PDF)

Impact of witnessing death on hospice patients

Social science & medicine (1982), 1996-12, Vol.43 (12), p.1785-1794

1996

Volltextzugriff (PDF)

Energy intake in pregnant women carrying boys or girls: difference is chance observation

BMJ (Online), 2003-09, Vol.327 (7415), p.622

2003

Volltextzugriff (PDF)

Go west

Columbia journalism review, 2013-11, Vol.52 (4), p.46

Langley, Alison

2013

Volltextzugriff (PDF)

Landing on its feet

The Institutional investor (U.S. ed.), 2006-03, p.1

Langley, Alison

2006

Volltextzugriff (PDF)

Landing on its feet: when it was spun off from Germany's HVB three years ago, Hypo Real Estate was a "bad" bank--stuck with 5 billion #8364; in dud loans and given scant chance of success. So how come it's flourishing?

Institutional investor (International ed.), 2006-03, Vol.31 (2), p.36

Langley, Alison

2006

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(46)
Humans
(39)
Female
(18)
Male
(18)
Aged
(13)
Adult
(10)
Middle Aged
(10)
Social Sciences
(10)
Patients
(9)
Biological And Medical Sciences
(8)
General & Internal Medicine
(8)
Oncology
(8)
Public, Environmental & Occupational Health
(8)
Adolescent
(7)
Covid-19
(7)
Medicine, General & Internal
(7)
Animals
(6)
Quality Of Life
(6)
Simulation
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Nausea and Vomiting of Pregnancy: Endocrine Basis and Contribution to Pregnancy Outcome

Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs)

Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs)

Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study

Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study

Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study

Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study

Light-hearted death talk in a palliative day care context

Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study

Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study

Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study

The mortality of mental illness in older age

Light-hearted death talk in a palliative day care context

'Suicide tourists' go to the Swiss for help in dying

Back to the Borse

Going local: 1

Reviving Swiss Life: 1

Impact of witnessing death on hospice patients

Energy intake in pregnant women carrying boys or girls: difference is chance observation

Go west

Landing on its feet

Landing on its feet: when it was spun off from Germany's HVB three years ago, Hypo Real Estate was a "bad" bank--stuck with 5 billion #8364; in dud loans and given scant chance of success. So how come it's flourishing?

Suchergebnisse filtern